0001209191-11-058045.txt : 20111125 0001209191-11-058045.hdr.sgml : 20111124 20111125160752 ACCESSION NUMBER: 0001209191-11-058045 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20111122 FILED AS OF DATE: 20111125 DATE AS OF CHANGE: 20111125 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Belle Gerald P. CENTRAL INDEX KEY: 0001416041 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-34275 FILM NUMBER: 111226842 MAIL ADDRESS: STREET 1: 320 WAKARA WAY CITY: SALT LAKE CITY STATE: UT ZIP: 84108 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Myrexis, Inc. CENTRAL INDEX KEY: 0001459450 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 263996918 STATE OF INCORPORATION: DE FISCAL YEAR END: 0630 BUSINESS ADDRESS: STREET 1: 305 CHIPETA WAY CITY: SALT LAKE CITY STATE: UT ZIP: 84108 BUSINESS PHONE: 801-214-7800 MAIL ADDRESS: STREET 1: 305 CHIPETA WAY CITY: SALT LAKE CITY STATE: UT ZIP: 84108 FORMER COMPANY: FORMER CONFORMED NAME: Myriad Pharmaceuticals, Inc. DATE OF NAME CHANGE: 20090324 4 1 c25239_4x0.xml MAIN DOCUMENT DESCRIPTION X0304 4 2011-11-22 0001459450 Myrexis, Inc. MYRX 0001416041 Belle Gerald P. C/O MYREXIS, INC. 305 CHIPETA WAY SALT LAKE CITY UT 84108 1 0 0 0 Common Stock 2011-11-22 4 P 0 34200 2.475 A 34500 D Common Stock 2011-11-23 4 P 0 6100 2.475 A 40600 D The shares were purchased in multiple transactions at prices ranging from $2.46 to $2.48 per share. The price reported above is the weighted average purchase price. See footnote (4) Includes 300 shares acquired on June 30, 2009 in a pro rata distribution by Myriad Genetics, Inc. ("Myriad Genetics") of all of its shares of the Issuer's common stock in connection with the spin-off of the Issuer by Myriad Genetics. The shares were purchased in multiple transactions at prices ranging from $2.46 to $2.48 per share. The price reported above is the weighted average purchase price. See footnote (4) The Reporting Person hereby undertakes to provide upon request to the staff of the SEC, the Issuer or a security holder of the Issuer, full information regarding the number of shares purchased at each separate price within the range set forth above. Ann Margaret Eames, Attorney-in-Fact 2011-11-25